CASE REPORT

Successful surgical treatment of a patient with primary insulinoma of the liver

A. Kriger1, S. Berelavichus2, D. Gorin3, G. Galkin4, M. Yukina5, I. Illovayskaya6, V. Zektser7, N. Nuralieva8 and A.R. Kaldarov9,*

1Department No.1 of A.V. Vishnevsky Center of Surgery, 5 Universitetsky Prospekt 289, Moscow 119296, Russia,
2Department No.1 of A.V. Vishnevsky Center of Surgery, 16/1 Solov’iny Proezd 139, Moscow 117593, Russia,
3Department No.1 of A.V. Vishnevsky Center of Surgery, 40 Seslavinskaya Street 48, Moscow 121309, Russia,
4Department No.1 of A.V. Vishnevsky Center of Surgery, 37/21 Tuhachevskogo Street 131, Moscow 123159, Russia,
5Department of National Medical Research Centre of Endocrinology, 11, Dm Ulyanova, Moscow 117036, Russia,
6Moscow Regional Research & Clinical Institute (MONIKI), 61/2 Schepkina Street, Moscow 129110, Russia,
7I.M. Sechenov First Medical State University, 8/2 Trubetskaya street, Moscow 119991, Russia,
8Department of National Medical Research Centre of Endocrinology 11, Dm Ulyanova, Moscow 117036, Russia and
9Department No.1 of A.V. Vishnevsky Center of Surgery, 9, Novoe Shosse 78, Drojino, Moscow 142718, Russia

*Correspondence address. 9, Novoe Shosse Street 78, Drojino, Moscow 142718, Russia. Tel: +7 (910) 4611737; Fax: +74992366306;
E-mail: ayratiku@gmail.com

Abstract

Insulinoma is the most frequent functional neuroendocrine tumor of the pancreas, which causes organic hyperinsulinism with severe hypoglycemia. There are no cases of primary insulinoma of the liver described. A 63-year-old female was admitted to our center presenting symptoms of severe hypoglycemia due to confirmed endogenic hyperinsulinism. None of the performed diagnostic procedures could reveal a pancreatic tumor. However, a pathologic mass in the sixth segment of the liver was detected. We performed arterial calcium stimulation that showed increased levels of insulin and c-peptide in almost all stimulated arteries. The highest and most prolonged peaks were detected at the points of the common hepatic artery and the right hepatic artery. After the surgical removal of the liver tumor, the blood glucose level was stabilized within the normal range. Post-operative pathomorphological investigation confirmed the diagnosis of a neuroendocrine tumor. The long-term survival results show correct treatment tactics without any signs of disease recurrence.
INTRODUCTION

Insulinoma is the most frequently occurring hormone-producing tumor of the pancreas, with malignancy signs in only 10–15% of cases. There are extremely rare cases of metastatic insulinoma described in the world literature. In about 1% of cases, insulinoma has an extrapancreatic origin and can be located in the splenic hilum, kidney or duodenum [1–3]. Here, we describe a case of successful surgical treatment of a patient with primary insulinoma of the liver.

CASE PRESENTATION

Female, 63 years old, was admitted to our hospital suffering from weakness, fainting and dizziness at a time of hypoglycemia, memory decline and decreased attention. She had experienced episodes of such symptoms during the previous 2 years. Hypoglycemia with a glucose level of 2.0 mmol/l had been detected during one of the episodes. For the next several months, the patient did not take any diagnostic tests. In 2017, the frequency of the hypoglycemic episodes increased. A fasting test was performed 2 years after the first episode in June 2018. The results showed hypoglycemia 0.91 mmol/l (normal range 3.0–5.5 mmol/l), insulin 54.4 mE/ml (normal range 3–26 mE/ml) and c-peptide 5.51 ng/ml (normal range 0.79–4.19 ng/ml). The patient was admitted to our hospital in normal condition. Her BMI was 39 kg/m2; total weight gain was 20 kg since the disease onset.

A transabdominal and endoscopic ultrasound also did not reveal any pathological findings in the pancreas. Contrast-enhanced CT and MRI scans of the abdominal cavity were then performed. A tumor of the pancreas was not revealed, although a pathologic mass in the sixth segment of the liver was detected (Fig. 1).

Due to being unable to identify a tumor of the pancreas and the pathological finding in the liver, we made a decision to perform arterial calcium stimulation with hepatic venous sampling (ASVS). The analysis showed increased insulin and c-peptide levels in almost all stimulated arteries. Moreover, the highest and most prolonged peaks of insulin and c-peptide levels were detected at the points of the common hepatic artery and the right hepatic artery (Fig. 2). This became the most important finding for further treatment.

Therefore, all performed diagnostic procedures (transabdominal US, endoscopic US, CT, MRI and ASVS) could not reveal a pancreatic tumor. However, the lesion of the liver looked like a neuroendocrine neoplasm.

DISCUSSION

In the described case, we expected to detect an insulin-producing pancreatic tumor which would have been a typical localization of insulinoma. Instead, we found a neoplasm in the liver parenchyma by instrumental diagnostics (CT, MRI, transabdominal and endoscopic ultrasound). We tried to differentiate this lesion either as a benign liver neoplasm, which was not associated with clinical symptoms, or as a metastasis of pancreatic insulinoma, which occurs extremely rarely [4–7].

There have been 92 patients operated with functional pancreatic neuroendocrine tumors in our hospital over the last 11 years, with no cases of metastatic insulinoma. In this case, the neoplasm in a pancreatic parenchyma was not revealed; therefore,
Successful surgical treatment of a patient with primary insulinoma of the liver

Figure 2: Diagrams of the ASVS. (A) Insulin levels and (B) c-peptide levels.

Figure 3: The specimen after surgery: (A) the view of the tumor and (B, C) microphotograph images of the tumor.

we decided to perform arterial calcium stimulation with hepatic venous sampling to confirm the pancreatogenic hyperinsulinism and possibly clarify the localization of the tumor. However, the data received after this analysis surprised us. Pathological insulin and c-peptide levels were observed at all points of stimulation excluding the artery pancreatica dorsalis and the proximal part of the splenic artery. The most unexpected fact was that pathological hormone levels were detected at points of stimulation of the common hepatic artery and, more importantly, the right hepatic artery.

Thus, we proved an organic hyperinsulinism. At the same time, we could not definitely state that it had pancreatogenic origins. Moreover, we hypothesized that a liver neoplasm could produce insulin. Therefore, we decided that the lesion of the
sixth segment of the liver was a hormone-producing metastasis of insulinoma without a detected primary tumor. We decided to perform an explorative laparotomy with intra-operative ultrasound. Intraoperatively, no pancreatic tumor was revealed. In this situation, considering the ASVS data with selective pathological levels of insulin and c-peptide from the right hepatic artery, we performed a liver resection. As the follow-up during a year and a half subsequent to surgery shows, the liver's tumor was the primary neuroendocrine neoplasm. The chosen tactics of treatment were correct. This was confirmed by control tests (CT, MRI and PET-CT) and the absence of hypoglycemia episodes.

There were an estimated 1067 cases of insulinoma in the study of Stefanini et al. Ectopic insulinomas were revealed in 1% of cases. The lesions were localized in the duodenum, the traits ligament, spleen or perisplenic space. However, the study results might be questionable due to the lack of diagnostics for the year of publication [2, 3].

However, there are sporadic cases of insulin-producing tumors which localized in the kidney, hepatoduodenal ligament, ovary and small pelvis [8–10]. We analyzed the world data (PubMed, MedScape and Cochrane) and could not find any cases of primary insulinomas of liver. There are some published cases about the ectopic pancreatic tissue in the liver. Therefore, we describe the first case of primary insulinoma of the liver. At this moment, follow-up control of the patient's condition is continued.

CONCLUSION

We present a case of a primary insulin-producing neuroendocrine tumor of the liver without any lesion elsewhere. It was confirmed by radiological and biochemical data and was successfully treated surgically. The short- and long-term survivals confirm that the symptoms were caused by the liver neoplasm.

PATIENT CONSENT

A written informed consent was obtained from the patient for publication of this case report and any accompanying images.

ACKNOWLEDGEMENTS

Marina Chuiko, Elena Dzeranova.

CONFLICT OF INTEREST STATEMENT

The authors declare of no conflicts of interests. The authors alone are responsible for the content and writing of the paper.

Research involving human participants and/or animals: this is a case presentation and no accessory research data is necessary.

FUNDING

The authors has not receive any grants or another funding resource for this paper.

REFERENCES

1. Podzolkov VI, Dragomiretskaia NA, Koroleva TV, Kvatradze NN, Iakovleva HH, Podzolkov AV. A rare case of hypoglycemia in an elderly patient with type 2 diabetes mellitus: malignant metastasizing insulinoma. Klin Med (Mosk) 2014;92:65–70.
2. La Rosa S, Pariani D, Calandra C, Marando A, Sessa F, Cortese F, et al. Ectopic duodenal insulinoma: a very rare and challenging tumor type. Description of a case and review of the literature. Endocrine Pathology 2013;24:213–9.
3. Stefanini P, Carboni M, Patrassi N, Basoli A. Beta-islet cell tumors of the pancreas: results of a study on 1,067 cases. Surgery 1974;75:597–609.
4. Yu J, Ping F, Zhang H, Li W, Yuan T, Fu Y, et al. Clinical Management of Malignant Insulinoma: a single Institution’s experience over three decades. BMC Endocr Disord 2018;18:92.
5. Liu Q, Duan J, Zheng Y, Luo J, Cai X, Tan H. Rare malignant insulinoma with multiple liver metastases derived from ectopic pancreas: 3-year follow-up and literature review. Onco Targets Ther 2018;11:1813–9.
6. Baldelli R, Ettorre G, Vennarecci G, Pasimeni G, Carboni F, Lorusso R, et al. Malignant insulinoma presenting as metastatic liver tumor. Case report and review of the literature. J Exp Clin Cancer Res 2007;26:603–7.
7. Caliri M, Verdiani V, Mannucci E, Briganti V, Landoni L, Esposito A, et al. A case of malignant insulinoma responsive to somatostatin analogs treatment. BMC Endocr Disord 2018;18:98.
8. Battocchio M, Zatelli MC, Chiarelli S, Trento M, Ambrosio MR, Pasquali C, et al. Ovarian tumors secreting insulin. Endocrine 2015;49:611–9.
9. Ramkumar S, Dhangra A, Jyotsna V, Ganie MA, Das CJ, Seth A, et al. Ectopic insulin secreting neuroendocrine tumor of kidney with recurrent hypoglycemia: a diagnostic dilemma. BMC Endocr Disord 2014;14:36.
10. Li TN, Liu Z, Zhang Y, Wang F. Ectopic insulinomas in the pelvis secondary to rectum neuroendocrine tumour. BMJ Case Rep 2018;2018:1–14.